• DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
DNDi - Best Science for the Most Neglected 20 Years
  • DNDi - Best Science for the Most Neglected 20 Years
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic Preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • HELP Helminth Elimination Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
      • DNDi Southern Africa
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > News

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Home > News

R&D Portfolio Update March 2018: DNDi Sleeping sickness programme

Medical staff looking into a microscope while screening patients in DRC
15 Mar 2018
Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on print

DNDi aims to deliver:

  • A safe, effective, and orally administered drug to replace current first-line HAT treatments, and to improve and simplify current case management.
  • The goal is to develop two drugs that are effective against both stages of the disease and both subspecies of the parasite (Trypanosoma brucei gambiense (g-HAT) and Trypanosoma brucei rhodesiense (r-HAT)).
  • If successful, this would represent a fundamental shift in disease management, as it would remove the need both for a risky and painful lumbar puncture test to confirm the disease stage, and for systematic hospitalization, as treatment would no longer rely on administering a drug intravenously.

DNDi’s current HAT portfolio includes:

Research

Research

Work in the research phase:

  • DNDi continues to provide support and advice to researchers working on discovery of new candidates for HAT and maintains two back-up candidates from the oxaborole class to ensure future development options if needed.

Development

Development

Two projects in the development phase:

  • Acoziborole (SCYX-7158): Phase I trials on this new chemical entity were completed in 2015, and allowed the therapeutic dose to be determined at 960mg, administered as a single dose of three tablets. A pivotal Phase II/III trial started in the last quarter of 2016. In 2017, recruitment continued with the inclusion of 76 patients (out of 210 patients in total) in eight clinical sites in DR Congo, including two new sites in Bandundu and Roi Baudoin Hospital (Katanda, Isangi, Dipumba, N’gandajika, Masi Manimba, Kwamouth, Bandundu, and Roi Baudoin Hospital in Kinshasa). One site (Bolobo) was closed in December 2017. Three more sites are planned to open in 2018, including one in Guinea.
  • Fexinidazole: Phase II/III study results published in 2017 confirmed that fexinidazole is safe and effective, and presents significant advantages over NECT, as it removes both the need for a lumbar puncture and systematic patient hospitalization. A regulatory dossier was submitted to the European Medicines Agency under Article 58 for the treatment of Trypanosoma brucei gambiense HAT (stages 1 and 2). Results were presented at ECTMIH in October 2017 and published in The Lancet. 

    A Phase IIIb trial to obtain more information about special populations not included in previous fexinidazole trials (including pregnant and lactating women, and patients with poor nutritional status or chronic diseases) started in 2016 and is ongoing. Patients are treated either in hospital, or at home, thereby also providing preliminary information about treatment compliance and final effectiveness in ambulatory patients.

    Recruitment continued in the Phase IIIb study with the inclusion of 45 patients (out of 174 in total) in five sites (Bandundu, Bagata, and Mushie, Masi Manimba, and Dipumba). Masi Manimba was opened in June 2017 and Dipumba in October 2017. An additional new site (Roi Baudouin Hospital, Kinshasa) was initiated in December and started recruitment in January 2018. Three more sites are planned to be opened in 2018, including one in Guinea.

    Two additional complementary cohorts with fexinidazole were completed in 2016, one including 230 adult patients with stage 1 and early stage 2 disease, and another including 125 children between 6 and 14 years, both at sites in DR Congo. Follow-up of patients was completed in 2017.

    In 2015, DNDi and the National HAT Control Programme (PNLTHA) of DR Congo completed the recruitment of 394 adult patients with stage 2 sleeping sickness at ten clinical sites in DR Congo and one supported by MSF in the Central African Republic, for a pivotal Phase II/III study to assess the efficacy and safety of fexinidazole in comparison with nifurtimox-eflornithine combination therapy (NECT) in stage 2 patients.

Implementation

Implementation

Implementation and Access:

  • NECT: Nifurtimox-eflornithine combination therapy (NECT) was included on the WHO Essential Medicines List in 2009 and extended to the Essential Medicines List for Children in 2013. With the recommendation of NECT as first-line treatment in all endemic countries, all of which receive free supplies from WHO via drug donations by Sanofi and Bayer, 100% of HAT stage 2 patients are now treated with NECT.
 
 
 

Photo credit: Neil Brandvold-DNDI

Strengthening Capacities Sleeping sickness

Read, watch, share

Loading...
Mark Sullivan
News
3 Oct 2023

Mark Sullivan joins the DNDi Scientific Advisory Committee

Centre of Excellence in India
News
14 Sep 2023

DNDi’s Centres of Excellence: Towards the sustainable elimination of visceral leishmaniasis in India

Delali Attip
Press releases
6 Sep 2023

Biotech leader Delali Attiogbe Attipoe joins DNDi as North America Director

Viewpoints
5 Sep 2023

Africa should bolster research into climate-sensitive diseases

Context
Prof. Sam Kariuki, DNDi Eastern Africa Director and Leonard Ithau, Rotary International District 9212 District Governor shaking hands
News
29 Aug 2023

DNDi and Rotary collaborate to prevent and treat diseases affecting neglected communities in Eastern Africa

Mother and child in a hospital
Viewpoints
24 Aug 2023

A drug development model for the diseases the world forgot

Africa Arguments
Statements
21 Aug 2023

DNDi urges G20 to operationalize equity in response to major global health challenges and priorities

Man looking into a microscope
Press releases
31 Jul 2023

Certara and DNDi partnering to fast-track data submissions and accelerate drug approvals for neglected patients

VIEW ALL

Help neglected patients

To date, we have delivered twelve new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
DNDi - Best Science for the Most Neglected 20 Years
Facebook-f
Twitter
Instagram
Linkedin-in
Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License   
This website uses necessary cookies to function. If you give your consent, we will also use statistical, functional, and marketing cookies. See Cookie Policy.
Customize
REJECT ACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-advertisement1 yearSet by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category .
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent1 yearRecords the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
PHPSESSIDsessionThis cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
CookieDurationDescription
elementorneverThis cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
CookieDurationDescription
_ga2 yearsThe _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
_ga_16Q5RH3XRG2 yearsThis cookie is installed by Google Analytics.
_gat_UA-10302561-11 minuteA variation of the _gat cookie set by Google Analytics and Google Tag Manager to allow website owners to track visitor behaviour and measure site performance. The pattern element in the name contains the unique identity number of the account or website it relates to.
_gid1 dayInstalled by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously.
_hjAbsoluteSessionInProgress30 minutesHotjar sets this cookie to detect the first pageview session of a user. This is a True/False flag set by the cookie.
_hjFirstSeen30 minutesHotjar sets this cookie to identify a new user’s first session. It stores a true/false value, indicating whether it was the first time Hotjar saw this user.
_hjIncludedInPageviewSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's pageview limit.
_hjIncludedInSessionSample2 minutesHotjar sets this cookie to know whether a user is included in the data sampling defined by the site's daily session limit.
_hjSession_112884430 minutesHotjar sets this cookie.
_hjSessionUser_11288441 yearHotjar sets this cookie.
CONSENT2 yearsYouTube sets this cookie via embedded youtube-videos and registers anonymous statistical data.
Targeting
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
SAVE & ACCEPT
Powered by CookieYes Logo